Flyrcado is a diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Be Flyrcado Forward
Join cardiovascular experts across the U.S. preparing to expand access to cardiac PET. Flyrcado Forward, GE HealthCare’s program of peer-to-peer education and training for cardiac PET imaging centers, is here to help.
Join us at SNMMI for a Breakfast Symposium
Advancing cardiac PET accessibility: Implementing shared cardiac PET services with FlyrcadoTM (flurpiridaz F 18) injection
Sunday, June 22 | 6:45 – 7:45 a.m. Ballroom R06-07, Level 2, New Orleans Convention Center
During this interactive session you will:
- Understand the clinical and operational advantages of a shared PET/CT MPI model.
- Hear first-hand insights from institutions already bringing cardiac PET to new patient populations.
- Leave with practical steps—and the confidence—to introduce Flyrcado into your own workflow.
Featured Speakers
Mouaz Al-Mallah, MD Houston Methodist
James Case, PhD Cardiovascular Imaging Technologies
About the session: Implementing a shared Myocardial Perfusion Imaging (MPI) PET/CT program, healthcare institutions can position themselves at the forefront of advanced cardiac imaging while optimizing resource utilization. Previously, however, implementing a shared program was hindered by the availability of cardiac PET tracers requiring an onsite cyclotron or generator. The introduction of FlyrcadoTM (flurpiridaz F 18) injection now provides accessibility of a unit dose cardiac PET tracer supplied from a local CMO allowing healthcare institutions to consider implementing a shared cardiac PET program without a large upfront financial commitment. This session will provide an overview of the practical considerations and clinical value of implementing a shared cardiac PET/CT MPI program with Flyrcado.
THE FIRST
NEW
F 18 MPI radiotracer in
OVER 20 YEARS
Gain greater diagnostic certainty in CAD
Flyrcado delivers precision in imaging1 and superior diagnostic accuracy over SPECT—even for challenging-to-image patients.2,3
Results from two large clinical trials demonstrate the superior sensitivity and non-inferior specificity of Flyrcado versus single-photon emission computed tomography (SPECT) MPI imaging in detecting coronary artery disease (CAD).
Enhance operational flexibility in cardiac PET
With on-demand unit doses delivered up to 5 days a week and a 109-minute half-life,1,2,4,5 Flyrcado enables operational flexibility for exercise stress testing and re-imaging due to technical difficulties, when needed, without re-dosing.2,4
Precision meets flexibility with Flyrcado
Versatile protocols due to longer half-life2,4,5
Superior image quality compared to SPECT1,2
Shorter positron range yields excellent resolution1
Support pharmacologic & exercise stress2
Convenience of unit dose delivered from local pharmacy1,6
Flyrcado brings cardiac PET to imaging centers in a broader range of sizes and locations4,5,7
Be Flyrcado Forward
At the 2025 SNMMI Annual Meeting, nuclear medicine leaders are coming together to explore the future
of nuclear medicine and molecular imaging.
We are excited to showcase Flyrcado at SNMMI 2025. Join your peers in the effort to expand access to cardiac PET imaging with the support of Flyrcado Forward. Sign up today for education and training opportunities with leading investigators and clinicians as you prepare to bring Flyrcado to your site of care.
Additional Support
- Flyrcado Support Line: 800 729 0701
- Medical Affairs: 800 654 0118
(option 2, then option 3) or [email protected] - Pharmacovigilance: 800 654 0118
(option 2, then option 1) or [email protected] - Clinical Applications: [email protected]
- Customer Service: 800 292 8514
Sign up for updates and resources to be Flyrcado Forward
References
- Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med. 2014;44(5):333-343.
- Flyrcado (flurpiridaz F 18 injection) . Full Prescribing Information. Marlborough, MA: GE HealthCare.
- Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial perfusion imaging in patients with suspected coronary artery disease. J Am Coll Cardiol. 2023;82(16):1598-1610.
- Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. Curr Cardiol Rep. 2022;24(8):987-994.
- Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging. 2017;33(7):1021-1031.
- Iskandrian AE, Dilsizian V, Garcia EV, et al. Myocardial perfusion imaging: lessons learned and work to be done update. J Nucl Cardiol. 2018;25(1):39-52.
- Bourque JM. Cardiac PET perfusion imaging: AURORA lights the way to a new era. J Am Coll Cardiol. 2023;82(16):1611-1613.
IMPORTANT SAFETY INFORMATION
Indications and Usage
FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
- Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information.
- Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.
Adverse Reactions
- Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch
Please see the full Prescribing Information for additional important safety information.
GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe
500 W. Monroe Street | Chicago, IL 60661
© 2025 GE HealthCare
Flyrcado is a trademark of GE HealthCare.
GE is a trademark of General Electric Company used under trademark license.
April 2025 | JB11555US